G
DHS has a requirement to continue the development and validation of its laboratory-based B. anthracis detection and diagnostic assays. To address these critical needs, Omni Array will continue to develop multiplex B. anthracis detection and surveillance assays, and multiplex Anthrax clinical diagnostic assays.
In the current contract, Omni Array was selected to develop a rapid Anthrax diagnostics test and also a multiplex (Luminex-based) rapid Abrin detection test. Omni Array is developing a novel multiplex Anthrax biomarker assay for clinical diagnostics testing and is at the completion stages of the rapid multiplex Abrin detection test. In addition to the above, Omni Array was also contracted to support DHS efforts in the validation of immunoassays to biothreat agents as a third party evaluation site.
The objective is to develop and deploy novel and innovative rapid first responder, clinical diagnostic, and biothreat agent detection assays capable of fulfilling the needs of multiple agencies and departments by multiplexing assays to detect simultaneously select biothreat agents. OmniArray is an assay developer with the capability, demonstrated experience, and required access to technology licenses to create immunologically based biothreat detection assays using the Luminex bead-based suspension assays. OmniArray is currently under contract, and is developing both biothreat detection and host-based immunological assays.
Note 22: This pre-award synopsis is for informational purposes only. Technical proposals will not be considered, however technical capability statements may be submitted, only if your organization has the technical capabilities necessary to meet the above stated needs. If such documents are submitted, they may be reviewed for consideration to open this requirement up for competition. The determination to open up the requirement to competition is at the sole discretion of the Government. All submissions become the property of the Federal Government, and will not be returned.